<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778579</url>
  </required_header>
  <id_info>
    <org_study_id>CART19-BE-02</org_study_id>
    <nct_id>NCT04778579</nct_id>
  </id_info>
  <brief_title>Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy</brief_title>
  <acronym>CART19-BE-02</acronym>
  <official_title>Phase 2 Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity (A3B1) Conjugated With the Co-stimulatory Regions 4-1BB and CD3z (ARI-0001 Cells) in Patients With CD19+ Acute Lymphoid Leukemia Resistant or Refractory to Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara V. Latorre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigacions Biomèdiques August Pi i Sunyer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigacions Biomèdiques August Pi i Sunyer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy (in terms of response rate and duration) of the infusion of ARI-0001&#xD;
      cells (Adult differentiated autologous T-cells from peripheral blood, expanded and&#xD;
      transducted with a lentivirus to express a chimeric antigen receptor with anti-CD19&#xD;
      specificity [A3B1] conjugated to the 4-aBB and CD3z co-stimulatory regions) in patients with&#xD;
      resistant or refractory CD19+ acute lymphoid leukemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>20 days after infusion</time_frame>
    <description>• Response rate with measurable residual disease negative by multiparametric flow cytometry</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Acute Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>ARI-0001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARI-0001 cells</intervention_name>
    <description>Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z</description>
    <arm_group_label>ARI-0001</arm_group_label>
    <other_name>CART19</other_name>
    <other_name>PEI 19-187</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnoses of CD19+ acute lymphoid leukemia, with a life expectancy of less than 2&#xD;
             years that meet the following conditions:&#xD;
&#xD;
               1. Relapsed/refractory not candidate for transplantation (due to associated diseases&#xD;
                  or absence of donor)&#xD;
&#xD;
               2. in allogenic post-transplant relapse.&#xD;
&#xD;
          2. Measurable disease understood as the presence of measurable residual disease by flow&#xD;
             cytometry in bone marrow or peripheral blood&#xD;
&#xD;
          3. Age less than 70 years (from 18 to 70).&#xD;
&#xD;
          4. ECOG functional status from 0 to 2&#xD;
&#xD;
          5. Life expectancy of at least 3 months.&#xD;
&#xD;
          6. Adequate venous access to perform a lymphapheresis. Absence of contraindications for&#xD;
             it.&#xD;
&#xD;
          7. Signature of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with any experimental or non-marketed substance within four weeks prior to&#xD;
             recruitment, or actively participating in another therapeutic trial.&#xD;
&#xD;
          2. Previous treatment with CART therapy (commercial or experimental)&#xD;
&#xD;
          3. Diagnosis of another neoplasm, past or present. Patients may be included in complete&#xD;
             remission for more than 3 years, or have a history of non-melanoma skin cancer or&#xD;
             in-situ carcinoma resected completely.&#xD;
&#xD;
          4. Relief of central nervous system (CNS-3) at the time of inclusion. Inclusion will be&#xD;
             permitted in patients with a lower grade (CNS-2) or CNS-3 who have responded to&#xD;
             intrathecal chemotherapy.&#xD;
&#xD;
          5. Isolated extramedullary involvement (i.e. in the absence of minimal residual disease&#xD;
             in peripheral blood, bone marrow, or cerebrospinal fluid)&#xD;
&#xD;
          6. Early relapse after transplantation (less than 3 months for mononuclear cell&#xD;
             apheresis, less than 6 months for infusion of ARI-0001)&#xD;
&#xD;
          7. Active immunosuppressive treatment for graft-versus-host disease and other diseases.&#xD;
             The use of corticosteroids to control leukaemia at the time of inclusion should be&#xD;
             limited as much as possible and should be discontinued prior to infusion of ARI-0001&#xD;
             cells.&#xD;
&#xD;
          8. Active infection requiring systemic medical treatment such as chronic kidney&#xD;
             infection, chronic lung infection or tuberculosis.&#xD;
&#xD;
          9. HIV infection.&#xD;
&#xD;
         10. Positive serology for hepatitis B, defined as a positive test for HBsAg. In addition,&#xD;
             if the patient is HBsAg negative but has anti-HBc antibodies it will be necessary to&#xD;
             perform a DNA test of the hepatitis B virus, and if the result is positive the patient&#xD;
             will be excluded&#xD;
&#xD;
         11. Positive serology for hepatitis C, defined as a positive test for anti-VHC antibodies&#xD;
             confirmed by RIBA&#xD;
&#xD;
         12. Concurrent uncontrolled medical illnesses including cardiac, renal, hepatic,&#xD;
             gastrointestinal, endocrine, pulmonary, neurological or psychiatric diseases that in&#xD;
             the opinion of the investigator are potential risk factors to the patient.&#xD;
&#xD;
         13. Severe organ involvement, defined as cardiac ejection fraction &lt;40%; DLCO &lt;40%;&#xD;
             calculated glomerular filtrate &lt;30 ml/min; or bilirubin &gt; 3 times the upper limit of&#xD;
             normality (unless Gilbert syndrome).&#xD;
&#xD;
         14. Pregnant or lactating women. Woman of childbearing potential should have a negative&#xD;
             pregnancy test in the screening phase.&#xD;
&#xD;
         15. Women of childbearing potential, including those whose last menstrual cycle was in the&#xD;
             year prior to screening, who are unable or unwilling to use highly effective&#xD;
             contraceptive methods* from the start of the study to the completion of the study.&#xD;
&#xD;
         16. Men who cannot or do not wish to use highly effective contraceptive methods* from the&#xD;
             beginning of the study until the end of the study&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jordi Esteve</last_name>
    <phone>+34932275400</phone>
    <email>jesteve@clinic.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentín Ortiz-Maldonado</last_name>
    <email>vortiz@clinic.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Torrent Catarineu, MD, PhD</last_name>
      <email>atorrent@ioncologia.net</email>
    </contact>
    <investigator>
      <last_name>Anna Torrent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose J Rifón, MD PhD</last_name>
      <email>jrifon@unav.es</email>
    </contact>
    <investigator>
      <last_name>José J Rifón</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Esteve, MD PhD</last_name>
      <phone>+34932275400</phone>
      <email>jesteve@clinic.cat</email>
    </contact>
    <contact_backup>
      <last_name>Valentín Ortiz-Maldonado, MD</last_name>
      <phone>+34932275400</phone>
      <email>vortiz@clinic.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Jordi Esteve</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentín Ortiz Maldonado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Briones Meijide</last_name>
      <email>jbriones@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Javier Briones Meijide</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose L Díez Martín, MD, PhD</last_name>
      <email>jdiezm@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>José L Díez Martín</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria L Paciello Coronel, MD, PhD</last_name>
      <email>mariapaciello@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria L Paciello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de La Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose M Moraleda, MD PhD</last_name>
      <email>jmoraled@um.es</email>
    </contact>
    <investigator>
      <last_name>Jose M Moraleda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dolores Caballero, MD PhD</last_name>
      <email>cabarri@usal.es</email>
    </contact>
    <investigator>
      <last_name>Dolores Caballero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital U. Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Blázquez</last_name>
      <email>cristinablazquezgoni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cristina Blazquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaime Sanz, MD PhD</last_name>
      <email>sanz_jai@gva.es</email>
    </contact>
    <investigator>
      <last_name>Jaime Sanz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigacions Biomèdiques August Pi i Sunyer</investigator_affiliation>
    <investigator_full_name>Sara V. Latorre</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

